UroGen Pharma (URGN)

• Market cap: $1.09B
• 1 day: 2.14%
• 5 days: 2.64%
• 1 month: -1.52%
• 3 months: 29.16%
• 6 months: 62.76%
• Year to date: 118.13%
• 1 year: 106.55%
• 5 years: 24.08%
• 10 years: 66.95%
• Sector: Healthcare
• Industry: Biotechnology

About: UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Employees: 253